<SEC-DOCUMENT>0001193125-16-702050.txt : 20160906
<SEC-HEADER>0001193125-16-702050.hdr.sgml : 20160906
<ACCEPTANCE-DATETIME>20160906164003
ACCESSION NUMBER:		0001193125-16-702050
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160906
FILED AS OF DATE:		20160906
DATE AS OF CHANGE:		20160906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		161871246

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d231701d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of September 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: 001-36697 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV
TECHNOLOGIES S.A. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>177-181 avenue Pierre Brossolette </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;Form 40-F </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated September 6, 2016.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"><B>DBV TECHNOLOGIES S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September 6, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Schilansky</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Schilansky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g231701g0906085237215.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle">


<IMG SRC="g231701g0906085237809.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g231701g0906085238012.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster
Vaccination </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proof of concept trial will evaluate the safety and immunogenicity of two doses of Viaskin rPT in healthy adults </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vaccine program to test Viaskin&#146;s needleless and adjuvant-free patch technology in reactivating pertussis toxin immunity </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PARIS, BANGKOK and GENEVA September 6, 2016 - </B>DBV Technologies (Euronext: DBV &#150; ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage
specialty biopharmaceutical company, the Geneva University Hospitals (HUG) and BioNet-Asia Co. Ltd today announced that the first subject has been enrolled in a proof of concept Phase I clinical trial testing Viaskin rPT in the reactivation of
immunity against Bordetella pertussis (whooping cough) in healthy adults. This pertussis vaccination program intends to test the ability of DBV&#146;s needleless and adjuvant-free patch technology, Viaskin, to epicutaneously deliver two doses of
BioNet&#146;s genetically detoxified, recombinant pertussis toxin (rPT) to boost immunity against whooping cough. The Phase I proof of concept study is being conducted under the supervision of Professor Claire-Anne Siegrist from the Clinical
Research Center of HUG and is being sponsored by DBV Technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr. Pierre-Henri Benhamou,</B> Chairman and Chief Executive Officer of DBV
Technologies, said:<I> &#147;Utilizing the skin&#146;s immune properties for vaccination is a paradigm shift in this field. Professor Siegrist and her team recently published a paper with pre-clinical data showing that a single application of
Viaskin rPT on intact skin was capable of reactivating whooping cough immunity without the use of adjuvants. This valuable collaboration with HUG and BioNet has the potential to be a breakthrough in vaccinations; if Professor Siegrist and her team
can replicate the in vivo results in humans, Viaskin rPT could be the first non-invasive and self-administrable vaccine to be developed for boosting pertussis immunity.&#148; </I><B>Dr. Benhamou continued, </B><I>&#147;Our commitment to developing
transformational products that can improve lives drives our innovation strategy at DBV. Enthusiasm for our unique patient-centric approach to immunotherapy was recently captured by the fast enrollment of our Viaskin Phase III trial in peanut
allergy. As in food allergies,</I><I>&nbsp;</I><I>our focus in vaccines is to develop novel products that can address unmet medical needs in an effective and safe way. We are excited to launch the rPT program, which continues to highlight the
strengths and versatility of our Viaskin technology platform.&#148;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant increase in the prevalence of pertussis, a highly contagious
respiratory illness, has been reported in a number of countries around the world, and it is associated with increased mortality in young infants. Pertussis vaccination is recommended as part of routine childhood immunization, but the immunity
acquired through vaccination or infection is short-lived, and its maintenance requires repeated boosting at regular time points. Viaskin&#146;s novel epicutaneous delivery technology may offer a more convenient, needleless and adjuvant-free option
for boosting pertussis immunization<B>.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Professor Claire-Anne Siegrist, </B>Director of the Center of Vaccinology of HUG, said: &#147;<I>We know that
regular boosters are needed to maintain protection against pertussis, and our preclinical studies showed that the reactivation of immune memory may be achieved using Viaskin. We are eagerly looking forward to assessing whether this is similarly
effective in humans, as the possibility of using needleless and adjuvant-free booster vaccines would be a change of paradigm in our approach to the prevention of pertussis and of other vaccine preventable diseases.&#148; </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr. Pham Hong Thai</B>, Chief Executive Officer of BioNet-Asia, said: <I>&#147;</I><I>Given the safety and superior immunogenicity of our recombinant
acellular pertussis vaccine as it was demonstrated in a Phase II/III trial, we are excited to explore alternative delivery options for BioNet</I><I>&#146;</I><I>s proprietary genetically inactivated pertussis toxin. </I><I>This promising
collaboration with DBV and HUG could be the first step to offerin</I><I>g a needle-free recombinant pertussis booster vaccine,</I><I> and it shows our commitment to deliver innovative solutions </I><I>for controlling the resurgence of pertussis
around the globe.</I><I>&#148;</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Phase I Viaskin rPT Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Phase I dose-escalation, randomized, double-blind, placebo-controlled safety and immunogenicity study will assess the safety of BioNet&#146;s
genetically-detoxified rPT administered by DBV&#146;s Viaskin patches in 60 young healthy adults. Secondary endpoints will assess the patients&#146; humoral responses elicited by Viaskin rPT 25 &micro;g and 50 &micro;g compared to placebo. Immune
cellular responses will also be monitored as exploratory endpoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trial will take place in the Clinical Research Center of HUG. Men and women aged
18-40 years who have been vaccinated during childhood against pertussis will be randomized into two cohorts of 30 subjects each. The first cohort will receive two applications of Viaskin rPT 25 &#371;g or placebo. The Viaskin patches will be applied
for 48 hours, with a two-week interval between applications. Four weeks after the second Viaskin application, participants will receive one dose of Boostrix<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> dTpa vaccine to ensure the recall
of immunity against diphtheria, tetanus and the three pertussis antigens (only a single antigen will be delivered through Viaskin rPT). All subjects will be observed after each application. Local and systemic adverse events will be monitored.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety and tolerability of the first dose of Viaskin rPT 25 &#371;g will be analyzed before initiating treatment in the second patient cohort, which is
expected to receive two applications of Viaskin rPT 50 &#371;g or placebo, and analysis of the results will follow the same study design as in the Viaskin rPT 25 &#371;g cohort. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Bordetella Pertussis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pertussis, commonly known as
whooping cough, is a highly contagious respiratory illness caused by a type of bacteria known as Bordetella pertussis. Pertussis vaccination is recommended as part of routine childhood immunization. Although the incidence of pertussis has declined
as a result of immunization of infants and young children, vaccine-induced immunity does not persist for long.&nbsp;This phenomenon, known as waning immunity, has increased since the introduction of acellular pertussis vaccines in 1996, which tend
to provide short-lived protection against the Bordetella pertussis bacteria. According to the U.S. Centers for Disease Control and Prevention (CDC), there are 16 million pertussis cases worldwide each year, mainly in adolescents and adults who often
can infect infants who have not yet completed their pertussis immunization. In these young patients, pertussis can be severe and fatal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Booster
immunizations are now recommended for adolescents and adults, but compliance is not always high. A new vaccine technology that is patient-friendly, painless and non-invasive could help increase the compliance for booster immunization against
whooping cough. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV Technologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV
Technologies is developing Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company
is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV&#146;s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies,
please visit our website: <U>www.dbv-technologies.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Geneva University Hospitals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Geneva University Hospitals (HUG), reference academic institution at both national and international level, gather eight public hospitals of Geneva. Their
centres of excellence cover hepato-biliary and pancreatic diseases, cardiovascular diseases, oncology, musculoskeletal and sports medicine, old age medicine, genetic medicine and vaccinology. Its Center of Vaccinology, led by Professor Claire-Anne
Siegrist, gained international recognition through the performance of a large first-in-humans Phase I randomized clinical trial that enrolled 115 subjects to characterize the safety and immunogenicity of the VSV-ZEBOV Ebola vaccine candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With their 10,500 employees, the HUG welcome each year 60,000 hospitalised patients and assure 91,000 emergencies, 990,000 consultations or ambulatory care
and 26,000 surgical procedures. More than 800 physicians, 3,000 interns and 150 apprentices perform their training here. The HUG are working closely with the Faculty of Medicine of the University of Geneva and WHO in various training and research
projects. They develop partnerships with CHUV, EPFL, CERN and other actors from the Lemanic Health Valley. More information on: <U>www.hug-ge.ch</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About BioNet-Asia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioNet-Asia offers access to vaccine
and technology through biotech innovation and partnering networks. BioNet has built several international partnerships fostering vaccine self-reliance and leading to the supply of billions of doses of vaccines worldwide. BioNet has also a broad
pipeline of vaccines in R&amp;D and clinical stages. BioNet most advanced program is the development of a new generation of pertussis vaccines aimed at overcoming the waning immunity observed with the conventional acellular pertussis vaccines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioNet pertussis vaccine is produced from a new proprietary <I>Bordetella pertussis</I> strain expressing genetically detoxified Pertussis Toxin (rPT). The
unique properties of BioNet rPT enables the vaccine to induce superior anti-PT immune response. BioNet has successfully demonstrated in a Phase II/III trial that its recombinant acellular pertussis vaccine (containing rPT and FHA), as standalone or
in combination, could significantly boost immunity against pertussis in adolescents and adults. For additional information, please visit <U>www.bionet-asia.com</U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward Looking Statements </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements, including statements about the potential safety and efficacy of Viaskin as a means of delivering&nbsp;recombinant pertussis toxin to boost immunity against Bordetella pertussis.&nbsp;These forward-looking statements are
not promises or guarantees and involve substantial risks and uncertainties.&nbsp;The Company&#146;s product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from
those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future
clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results.&nbsp;A further list and description of these risks, uncertainties and other risks can be found in the Company&#146;s
regulatory filings with the French Autorit&eacute; des March&eacute;s Financiers, the Company&#146;s Securities and Exchange Commission filings and reports, including in the Company&#146;s Annual Report on Form 20-F for the year ended December 31,
2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation
to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Susanna Mesa </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President, Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 212-271-0861 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">susanna.mesa@dbv-technologies.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Erinn White, Centron PR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1-646-722-8822 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ewhite@centronpr.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact Europe </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Caroline Carmagnol, Alize RP, Relations Presse </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+33 (0)6
64 18 99 59</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">caroline@alizerp.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Geneva University Hospitals Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Professor Claire-Anne Siegrist, Director of the Center of Vaccinology </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+41(22) 379 57 77 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">claire-anne.siegrist@unige.ch </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HUG Media Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nicolas de Saussure, PR Officer
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+41&nbsp;(22)&nbsp;372&nbsp;60&nbsp;06 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">nicolas.desaussure@hcuge.ch </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BioNet Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Laurent Dapremont, Director Strategic Business Development, BioNet-Asia Co. Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+66 (2) 361 8110 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">laurent.d@bionet-asia.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g231701g0906085237215.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g231701g0906085237215.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N &$# 2(  A$! Q$!_\0
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M* "N2G7_ (2#Q>T$AS8:6 SKV>4^OTKK:X;1YVB\-^([_),SW,Q)'7@<?SH
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MS0!'JMILL-!\.)@R22(\H'95Y)KM)98[>)I975(U&2S' %<KI@-N]SXGUQA
M\B[8D;_EFG8?4U'#;7GC"=;J\#V^CJ<Q0=&F]V]J +3^+FNI6CTC3;B^ .#(
M!M3\S5O2]2UJZO?+OM)%K#M)\P2[N?3%;$$$5M$L4,:QQJ,!5& *DH ****
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<Q1J25103UP*541!A%"Y]!2<DQJ+0ZBBBI*/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g231701g0906085237809.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g231701g0906085237809.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U .,# 2(  A$! Q$!_\0
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MC\)Z:ARPED_WG_PK3MM.L[,?N+=$]P.:**5RHTH1V1:HHHH+$*AAA@"/<4
M#   ]***    8  %+110 F #D 9-+110 F!G.!GUI:** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g231701g0906085238012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g231701g0906085238012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U ,8# 2(  A$! Q$!_\0
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M2K"( @C!%% '/_$7_D"VW_7P/_037FM>E?$7_D#6W_7<?^@FO-<'TKZ7+/\
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9D#%%% %ZWMXK6W2"! D:#"J.U%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
